Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of E6742 in Healthy Adults
NCT03082235Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of e6742 in systemic lupus erythematosus (SLE) (14 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with any serious adverse event and number of participants with any non-serious adverse event, Mean maximum observed concentration (Cmax) of E6742 and the metabolite ER-1132963 in plasma and 11 more. Started Mar 2017; status: completed.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03082235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082235.